

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

CIN - L51900MH1985PLC035738

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2015**

**PART I**

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/12/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Income from Operations</b>						
	a) Net Sales/Income from Operations	10,703.44	11,689.57	17,275.08	32,456.00	54,532.25	66,695.07
	b) Other Operating Income	98.92	118.69	100.52	360.14	292.89	368.20
	<b>c) Total Income from Operations</b>	<b>10,802.36</b>	<b>11,808.26</b>	<b>17,375.60</b>	<b>32,816.14</b>	<b>54,825.14</b>	<b>67,063.27</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	6,358.94	7,971.45	21,248.84	31,660.21	52,986.94	61,783.87
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	923.77	(347.48)	(8,790.05)	(9,972.34)	(15,279.28)	(15,232.62)
	d) Employee benefits expense	1,301.14	1,345.48	1,289.83	3,873.61	3,950.41	5,167.27
	e) Depreciation and amortization expense	7,020.70	7,017.02	6,382.47	21,087.27	19,177.09	27,657.43
	f) Other Expenses	731.75	702.51	850.91	2,316.25	2,920.59	3,852.80
	<b>g) Total Expenses</b>	<b>16,336.30</b>	<b>16,688.98</b>	<b>20,982.00</b>	<b>48,965.00</b>	<b>63,755.75</b>	<b>83,228.75</b>
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(5,533.94)</b>	<b>(4,880.72)</b>	<b>(3,606.40)</b>	<b>(16,148.86)</b>	<b>(8,930.61)</b>	<b>(16,165.48)</b>
<b>4</b>	<b>Other Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>5</b>	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(5,533.94)</b>	<b>(4,880.72)</b>	<b>(3,606.40)</b>	<b>(16,148.86)</b>	<b>(8,930.61)</b>	<b>(16,165.48)</b>
<b>6</b>	<b>Finance Costs</b>	<b>8,411.97</b>	<b>8,217.04</b>	<b>12,857.94</b>	<b>24,268.37</b>	<b>38,190.74</b>	<b>46,950.57</b>
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(13,945.91)</b>	<b>(13,097.76)</b>	<b>(16,464.34)</b>	<b>(40,417.23)</b>	<b>(47,121.35)</b>	<b>(63,116.05)</b>
<b>8</b>	<b>Tax expense</b>						
	a) Current	0.00	0.00	0.00	0.00	0.00	0.00
	b) Deferred	(4,525.00)	(4,250.00)	(5,342.00)	(13,114.00)	(15,289.00)	(20,478.00)
	<b>c) Total</b>	<b>(4,525.00)</b>	<b>(4,250.00)</b>	<b>(5,342.00)</b>	<b>(13,114.00)</b>	<b>(15,289.00)</b>	<b>(20,478.00)</b>
<b>9</b>	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(9,420.91)</b>	<b>(8,847.76)</b>	<b>(11,122.34)</b>	<b>(27,303.23)</b>	<b>(31,832.35)</b>	<b>(42,638.05)</b>
<b>10</b>	<b>Extraordinary Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>11</b>	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(9,420.91)</b>	<b>(8,847.76)</b>	<b>(11,122.34)</b>	<b>(27,303.23)</b>	<b>(31,832.35)</b>	<b>(42,638.05)</b>
<b>12</b>	<b>Prior year adjustment</b>	<b>0.00</b>	<b>0.00</b>	<b>(550.00)</b>	<b>0.00</b>	<b>(1,200.00)</b>	<b>(3,132.47)</b>
<b>13</b>	<b>Profit available for appropriation</b>	<b>(9,420.91)</b>	<b>(8,847.76)</b>	<b>(11,672.34)</b>	<b>(27,303.23)</b>	<b>(33,032.35)</b>	<b>(45,770.52)</b>
<b>14</b>	<b>Paid-up equity share capital (Face Value of Re.1/- per share)</b>	<b>2,720.48</b>	<b>2,720.48</b>	<b>2,720.48</b>	<b>2,720.48</b>	<b>2,720.48</b>	<b>2,720.48</b>
<b>15</b>	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>						<b>101,026.03</b>
<b>16.i</b>	<b>Earnings Per Equity Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)</b>						
	a) Basic	(3.46)	(3.25)	(4.09)	(10.04)	(11.70)	(15.67)
	b) Diluted	(2.18)	(2.04)	(2.57)	(6.31)	(7.35)	(9.85)
<b>16.ii</b>	<b>Earnings Per Equity Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)</b>						
	a) Basic	(3.46)	(3.25)	(4.29)	(10.04)	(12.14)	(16.82)
	b) Diluted	(2.18)	(2.04)	(2.70)	(6.31)	(7.63)	(10.57)

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

CIN - L51900MH1985PLC035738

Select Information for the Quarter ended 30 September 2015

**PART II**

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/12/2014
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
<b>1</b>	Public Shareholding						
	- Number of Equity shares	135,545,090	135,545,090	135,545,090	135,545,090	135,545,090	135,545,090
	- Percentage of shareholding	49.82%	49.82%	49.82%	49.82%	49.82%	49.82%
<b>2</b>	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of Equity shares	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	55.94%	55.94%	55.94%	55.94%	55.94%	55.94%
	Percentage of shares (as a % of the total Equity share capital of the Company)	18.68%	18.68%	18.68%	18.68%	18.68%	18.68%
	b) Non-encumbered						
	Number of Equity shares	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	44.06%	44.06%	44.06%	44.06%	44.06%	44.06%
	Percentage of shares (as a % of the total Equity share capital of the Company)	14.71%	14.71%	14.71%	14.71%	14.71%	14.71%

Sr. No.	Particulars	Quarter ended 30/09/2015
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 6 November 2015.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 September 2015
- 4 The Company has Overseas Subsidiaries and there are no business operations in the subsidiary companies.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

**Chetan J. Sandesara  
Joint Managing Director  
DIN - 00255671**

Place : Mumbai  
Date : 6 November 2015.